Valuation: TrivarX Limited

Market Cap 24.23M 16.95M 14.73M 13.76M 12.63M 23.81M 1.62B 162M 63.53M 806M 63.68M 62.27M 2.66B P/E 2024
-5.79x
P/E 2025 -4.2x
Enterprise Value 23.15M 16.2M 14.08M 13.14M 12.07M 22.75M 1.54B 155M 60.7M 770M 60.85M 59.5M 2.54B EV / Sales 2024
10.6x
EV / Sales 2025 3.76x
Free-Float
74.67%
Yield 2024 *
-
Yield 2025 -
1 day+969.23%
1 month+969.23%
3 months+1,012.00%
6 months+1,012.00%
Current year+77.07%
1 month 0.03
Extreme 0.0278
0.03
Current year 0
Extreme 0.0025
0.03
1 year 0
Extreme 0.0025
0.03
3 years 0
Extreme 0.0021
0.03
5 years 0
Extreme 0.0021
0.26
10 years 0
Extreme 0.0021
7.2
Manager TitleAgeSince
Chief Executive Officer - 01/06/2026
Chief Operating Officer - 01/01/2023
Corporate Secretary - 01/04/2026
Director TitleAgeSince
Chairman - 26/10/2022
Director/Board Member - 15/02/2023
Director/Board Member - 29/07/2024
Change 5-day change 1-year change 3-year change Capi.($)
+969.23%-.--% - - 12.96M
-2.48%-2.66%+59.38%+20.38% 322B
-0.49%+0.49%+31.65%-13.19% 71.6B
-0.10%+1.36%+37.67%+96.18% 9.79B
-1.53%-3.92%-2.67%-7.72% 8.39B
-0.76%-2.73%-16.42%-13.85% 4.3B
+0.14%-1.74%-34.69%+6.15% 3.81B
-2.35%-3.72%-14.99%+13.09% 3.58B
+6.51%+3.43%+31.15%+52.56% 2.59B
+0.47%+10.40%+0.22%-2.76% 2.25B
Average +97.18%+0.44%+10.14%+16.76% 47.54B
Weighted average by Cap. -1.59%-0.03%+50.32%+15.49%

Financials

2024 2025
Net sales 889K 622K 541K 505K 463K 874K 59.29M 5.95M 2.33M 29.56M 2.34M 2.28M 97.52M 1.03M 722K 627K 585K 537K 1.01M 68.77M 6.9M 2.7M 34.3M 2.71M 2.65M 113M
Net income -1.43M -1M -873K -815K -748K -1.41M -95.69M -9.61M -3.76M -47.72M -3.77M -3.69M -157M -943K -660K -574K -536K -492K -927K -62.91M -6.32M -2.47M -31.37M -2.48M -2.42M -103M
Net Debt -832K -582K -506K -472K -434K -818K -55.5M -5.57M -2.18M -27.68M -2.19M -2.14M -91.29M -1.08M -754K -656K -612K -562K -1.06M -71.89M -7.22M -2.83M -35.85M -2.83M -2.77M -118M
Logo TrivarX Limited
TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.
Employees
6